Federated Hermes Inc. grew its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 11.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,420,638 shares of the company's stock after buying an additional 876,624 shares during the period. Federated Hermes Inc. owned 0.44% of Kenvue worth $179,781,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Waterloo Capital L.P. purchased a new position in shares of Kenvue in the 4th quarter worth $288,000. Envestnet Asset Management Inc. raised its stake in shares of Kenvue by 79.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 10,224,056 shares of the company's stock valued at $218,284,000 after purchasing an additional 4,523,918 shares during the period. Aviva PLC lifted its position in shares of Kenvue by 1,159.8% during the fourth quarter. Aviva PLC now owns 1,154,701 shares of the company's stock worth $24,653,000 after purchasing an additional 1,063,043 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new position in shares of Kenvue in the fourth quarter valued at $13,601,000. Finally, Prudential PLC grew its holdings in Kenvue by 1,699.1% during the 4th quarter. Prudential PLC now owns 574,143 shares of the company's stock valued at $12,258,000 after purchasing an additional 542,231 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on KVUE shares. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Barclays increased their price objective on shares of Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Thursday, March 27th. Finally, Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $23.96.
Read Our Latest Report on KVUE
Kenvue Stock Performance
Shares of Kenvue stock traded up $0.19 on Friday, reaching $22.06. 3,792,974 shares of the company were exchanged, compared to its average volume of 16,885,775. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm has a market cap of $42.15 billion, a price-to-earnings ratio of 41.58, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company's 50-day moving average is $22.62 and its two-hundred day moving average is $22.41.
Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.72%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is currently 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
